It appears to the Securities and Exchange Commission that the public interest and the protection of investors require a suspension of trading in the securities of Blackhawk Growth Corp. (“Blackhawk”) (CIK No. 0000863710) due to questions and concerns regarding the accuracy and adequacy of publicly available information concerning Blackhawk and the market for its securities, including public statements made by Blackhawk in press releases dated April 22 and 29, 2020, and May 10 and 11, 2020, and in video interviews dated April 16 and 22, 2020, and May 1, 2020, regarding Blackhawk’s purported agreement to distribute COVID-19 antibody test kits in the United States and other countries, and its sales and delivery of those test kits. Blackhawk was incorporated in Alberta, Canada and has its principal offices purportedly in Calgary, Alberta. As of June 17, 2020, Blackhawk’s common stock was quoted on OTC Link (previously “Pink Sheets”) operated by OTC Markets Group, Inc. under the ticker symbol BLRZF.

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company.
THEREFORE, IT IS ORDERED, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed company is suspended for the period from 9:30 a.m. EDT, on June 23, 2020 through 11:59 p.m. EDT, on July 7, 2020.

By the Commission.

Vanessa A. Countryman
Secretary